Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 24

1.

The impact of disease activity and tumor necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.

Walters HM, Pan N, Lehman TJ, Adams A, Kalliolias GD, Zhu YS, Santiago F, Nguyen J, Sitaras L, Cunningham-Rundles S, Walsh TJ, Toussi SS.

Clin Exp Immunol. 2016 Mar 2. doi: 10.1111/cei.12782. [Epub ahead of print]

PMID:
26934060
2.

TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Kalliolias GD, Ivashkiv LB.

Nat Rev Rheumatol. 2016 Jan;12(1):49-62. doi: 10.1038/nrrheum.2015.169. Epub 2015 Dec 10. Review.

PMID:
26656660
3.

Blood-induced arthropathy in hemophilia: mechanisms and heterogeneity.

Blobel CP, Haxaire C, Kalliolias GD, DiCarlo E, Salmon J, Srivastava A.

Semin Thromb Hemost. 2015 Nov;41(8):832-7. doi: 10.1055/s-0035-1564445. Epub 2015 Oct 9.

PMID:
26451745
4.

Prolonged tumor necrosis factor α primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin.

Sohn C, Lee A, Qiao Y, Loupasakis K, Ivashkiv LB, Kalliolias GD.

Arthritis Rheumatol. 2015 Jan;67(1):86-95. doi: 10.1002/art.38871.

5.

Modulation of TNF-induced macrophage polarization by synovial fibroblasts.

Donlin LT, Jayatilleke A, Giannopoulou EG, Kalliolias GD, Ivashkiv LB.

J Immunol. 2014 Sep 1;193(5):2373-83. doi: 10.4049/jimmunol.1400486. Epub 2014 Jul 23.

6.

Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis.

Chakravarty SD, Poulikakos PI, Ivashkiv LB, Salmon JE, Kalliolias GD.

Clin Immunol. 2013 Jul;148(1):66-78. doi: 10.1016/j.clim.2013.04.007. Epub 2013 Apr 17. Review.

PMID:
23651870
7.

iRHOM2 is a critical pathogenic mediator of inflammatory arthritis.

Issuree PD, Maretzky T, McIlwain DR, Monette S, Qing X, Lang PA, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD, Yarilina A, Horiuchi K, Ivashkiv LB, Mak TW, Salmon JE, Blobel CP.

J Clin Invest. 2013 Feb;123(2):928-32. doi: 10.1172/JCI66168. Epub 2013 Jan 25.

8.

Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.

Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, Ivashkiv LB, Kalliolias GD.

Arthritis Rheum. 2013 Apr;65(4):928-38. doi: 10.1002/art.37853.

9.
10.

Type I interferons as biomarkers in autoimmune diseases.

Kalliolias GD, Kirou KA.

Biomark Med. 2012 Apr;6(2):137-40. doi: 10.2217/BMM.12.8. No abstract available.

11.

Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.

Kalliolias GD, Gordon RA, Ivashkiv LB.

J Immunol. 2010 Dec 1;185(11):7047-56. doi: 10.4049/jimmunol.1001290. Epub 2010 Oct 22.

12.

A new tool for detection of type I interferon activation in systemic lupus erythematosus.

Kirou KA, Kalliolias GD.

Arthritis Res Ther. 2010;12(4):138. doi: 10.1186/ar3114. Epub 2010 Aug 26.

13.

Overview of the biology of type I interferons.

Kalliolias GD, Ivashkiv LB.

Arthritis Res Ther. 2010;12 Suppl 1:S1. doi: 10.1186/ar2881. Epub 2010 Apr 14.

14.

Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins.

Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, Arthur JS, Kalliolias GD, Ivashkiv LB.

Immunity. 2010 Apr 23;32(4):518-30. doi: 10.1016/j.immuni.2010.03.014. Epub 2010 Apr 1.

15.

Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages.

Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3012-7. doi: 10.1073/pnas.0914902107. Epub 2010 Jan 26.

16.

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB.

Arthritis Rheum. 2010 Feb;62(2):402-13. doi: 10.1002/art.27200.

17.

Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation.

Kalliolias GD, Ivashkiv LB.

F1000 Biol Rep. 2009 Sep 8;1:70. doi: 10.3410/B1-70.

18.

Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy.

Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA, Ifanti A, Kalofonos HP.

Eur J Cancer Care (Engl). 2008 Nov;17(6):535-41. doi: 10.1111/j.1365-2354.2007.00857.x. Epub 2008 Aug 13.

PMID:
18707621
20.

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.

Kalliolias GD, Liossis SN.

Expert Opin Investig Drugs. 2008 Mar;17(3):349-59. doi: 10.1517/13543784.17.3.349 . Review.

PMID:
18321234
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk